Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?

Dementia is a progressive disorder that typically worsens with time and from which recovery is unlikely. The incidence of dementia increases exponentially with ageing and is an important public health challenge. There is now growing evidence for the role of vascular factors in Alzheimer’s disease, mixed dementia (Alzheimer’s disease with cerebrovascular disease), and of course vascular dementia. With the rising prevalence of vascular disease, there are increasing numbers of people who are identified to be at risk of cognitive impairment. By changing modifiable vascular risk factors, there is emerging evidence that it may be possible to prevent or delay the expression and progression of dementia.

[1]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[2]  H Matsuda,et al.  Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Barrio,et al.  P-79: The effect of blood pressure control on cognitive function (the focus study) , 2001 .

[4]  B. Winblad,et al.  Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. , 1999, Archives of neurology.

[5]  C. Schweiger [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[6]  M. Béné,et al.  CSF-folate levels are decreased in late-onset AD patients , 2001, Journal of Neural Transmission.

[7]  Annalena Venneri,et al.  Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease , 2002, Neuroreport.

[8]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[9]  J. Benito-León,et al.  Serum levels of β‐carotene, α‐carotene and vitamin A in patients with Alzheimer's disease , 1999, European journal of neurology.

[10]  E. Barrett-Connor,et al.  Serum lipoprotein levels, statin use, and cognitive function in older women. , 2002, Archives of neurology.

[11]  D. Fuchs,et al.  Homocysteine and B vitamins in dementia. , 2001, The American journal of clinical nutrition.

[12]  S. Mayor Regulatory authorities review use of galantamine in mild cognitive impairment , 2005, BMJ : British Medical Journal.

[13]  B. Winblad,et al.  An active and socially integrated lifestyle in late life might protect against dementia , 2004, The Lancet Neurology.

[14]  R. Brookmeyer,et al.  Survival following a diagnosis of Alzheimer disease. , 2002, Archives of neurology.

[15]  R. L. Rogers,et al.  Randomized Clinical Trial of Daily Aspirin Therapy in Multi‐Infarct Dementia , 1989, Journal of the American Geriatrics Society.

[16]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[17]  A. Hofman,et al.  The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization , 2004, Journal of hypertension.

[18]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[19]  Laura Fratiglioni,et al.  Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. , 2002, American journal of epidemiology.

[20]  G. Reaven,et al.  Verbal Learning and/or Memory Improves with Glycemic Control in Older Subjects with Non‐Insulin‐Dependent Diabetes Mellitus , 1993, Journal of the American Geriatrics Society.

[21]  S. Cummings,et al.  Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. , 2005, The American journal of psychiatry.

[22]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[23]  B. Singer,et al.  Price of adaptation--allostatic load and its health consequences. MacArthur studies of successful aging. , 1997, Archives of internal medicine.

[24]  M. Mattson,et al.  Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[25]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[26]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[27]  Qiang Xu,et al.  Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins , 2002, Brain Research.

[28]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Lindsay,et al.  Physical activity and risk of cognitive impairment and dementia in elderly persons. , 2001, Archives of neurology.

[30]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[31]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Hensley,et al.  Oxidative stress in brain aging Implications for therapeutics of neurodegenerative diseases , 2002, Neurobiology of Aging.

[33]  G. Vega,et al.  Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. , 2003, Archives of neurology.

[34]  B. Winblad,et al.  Statins in the Prevention and Treatment of Alzheimer Disease , 2002, Alzheimer disease and associated disorders.

[35]  D. Fuchs,et al.  Hyperhomocysteinemia in dementia , 2000, Neurobiology of Aging.

[36]  Jiankang Liu,et al.  Stress, Aging, and Brain Oxidative Damage , 1999, Neurochemical Research.

[37]  Paolo Vitali,et al.  Hippocampal perfusion in mild Alzheimer's disease , 2000, Psychiatry Research: Neuroimaging.

[38]  N. Cohen,et al.  Aerobic fitness reduces brain tissue loss in aging humans. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[39]  S. Kalmijn Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. , 2000, The journal of nutrition, health & aging.

[40]  H. Tuokko,et al.  The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. , 1993, Journal of gerontology.

[41]  D. Blacker Mild cognitive impairment--no benefit from vitamin E, little from donepezil. , 2005, The New England journal of medicine.

[42]  Yvette I. Sheline,et al.  Depression Duration But Not Age Predicts Hippocampal Volume Loss in Medically Healthy Women with Recurrent Major Depression , 1999, The Journal of Neuroscience.

[43]  Denis A. Evans,et al.  Vitamin E and cognitive decline in older persons. , 2002, Archives of neurology.

[44]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[45]  M. Grundman,et al.  Antioxidant strategies for Alzheimer's disease , 2002, Proceedings of the Nutrition Society.

[46]  A. Hofman,et al.  Dietary fat intake and the risk of incident dementia in the Rotterdam study , 1997, Annals of neurology.

[47]  J. Ramsdell,et al.  Nutritional status of free-living Alzheimer's patients. , 1989, The American journal of the medical sciences.

[48]  H. Dodge,et al.  Use of Lipid‐Lowering Drugs in Older Adults With and Without Dementia: A Community‐Based Epidemiological Study , 2002, Journal of the American Geriatrics Society.

[49]  E. Feskens,et al.  Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. , 1997, American journal of epidemiology.

[50]  J. Dichgans,et al.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial , 2002, Annals of neurology.

[51]  V. Hirth,et al.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[52]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[53]  K Yaffe,et al.  A prospective study of physical activity and cognitive decline in elderly women: women who walk. , 2001, Archives of internal medicine.

[54]  B. Vellas,et al.  Low plasma vitamin C in Alzheimer patients despite an adequate diet , 1998, International journal of geriatric psychiatry.

[55]  B. Winblad,et al.  Vitamin B12 and folate in relation to the development of Alzheimer’s disease , 2001, Neurology.

[56]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[57]  Robert B. Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003 .